Date:10/29/2009

---- ---- ---- ---- GAAP net earnings $1.5 $24.1 $82.9 $110.9 Income taxes (2.0) 1.8 13.2 30.5 Interest expense 24.3 16.7 52.7 44.5 Depreciation and amortization 80.6 69.7 219.4 192.1 EBITDA 104.4 112.3 368.2 378.0 Reconciling items: Restructuring and acquisition related costs (a) 79.2 7.8 127.2 13.2 Foreign currency gains related to ODS acquisition (b) (18.0) - (26.7) - Fair market value inventory adjustment ( c ) 8.8 - 8.8 1.0 Inventory write-off (d) 1.6 - 1.6 - Purchase of sublicense-Molecular testing (f) 5.8 - 5.8 12.0 Litigation accrual (g) 3.9 - 3.9 - Miami vacant land sale (h) - - - (1.2) Environmental remediation (i) - 19.0 - 19.0 Royalty buy out (j) - 11.7 - 11.7 Adjusted EBITDA $185.7 $150.8 $488.8 $433.7 (1) Amounts may not foot due to rounding. (2) See accompanying Non-GAAP Financial Measures section for description of Non-GAAP adjustments.

                              BECKMAN COULTER, INC.
               RECONCILIATION OF GAAP TOTAL NON-OPERATING EXPENSE TO
                    ADJUSTED TOTAL NON-OPERATING EXPENSE  (1) (2)
                     (in millions, except amounts per share)
                                  (unaudited)

                                        Quarter Ended     Nine Months Ended
                                         September 30,       September 30,
                              
'/>"/>
SOURCE  Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results